{"schema_version":"secwatch.filing_event.v1","accession":"0001824293-23-000018","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2023-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.831073+00:00","generated_at":"2026-06-19T00:54:08.443701+00:00","sec_items":["2.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vallon Pharma reports FY2022 net loss of $7.0M; merges with GRI Bio in all-stock deal","bullets":["Net loss of $7.0M for FY2022 vs. $9.3M in FY2021; R&D expenses fell to $1.2M from $5.2M.","Cash and cash equivalents of $3.8M as of Dec 31, 2022.","Definitive merger agreement with GRI Bio: all-stock transaction; combined company to operate as GRI Bio, Inc. under ticker 'GRI'.","Merger expected to close in Q2 2023; focus on NKT cell regulators for inflammatory, fibrotic and autoimmune diseases.","G&A expenses rose to $5.8M from $4.1M due to evaluation of strategic alternatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001824293-23-000018","json":"https://secwatch.observer/filing/0001824293-23-000018.json","markdown":"https://secwatch.observer/filing/0001824293-23-000018.md","text":"https://secwatch.observer/filing/0001824293-23-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000018/0001824293-23-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000018/val-20230224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T00:54:08.443701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31aea2a1aa9ad5777dc55a6c5dedfe84e2a1a98a","claim":"GRI Bio, Inc. reported the fiscal year ended December 31, 2022 results: net income $7.0 million.","evidence_excerpt":"Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results PHILADELPHIA, PA, February 24, 2023 – Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today reported its financial results for the fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000018/0001824293-23-000018-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Net income","value":"$7.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}